Weikel W, Brumm C, Wilkens C, Beck T, Knapstein P G
Department of Gynecology and Obstetrics, Universitäts-Frauenklinik Mainz, Germany.
Cancer Detect Prev. 1995;19(5):446-50.
We determined the growth fraction in 549 primary breast carcinomas using monoclonal antibody Ki-67. With respect to the course of disease, significant differences emerged for the whole collective as well as among the node-positive tumors. We paid special attention to the node-negative (N0) carcinomas in the group, the aim being to differentiate a prognostically unfavorable subgroup in this otherwise favorable collective. Owing to the comparative rarity of clinical events, our findings for such tumors failed to attain statistical significance; however, a strong clinical trend indicating an adverse prognosis for both overall and disease-free survival emerged for tumors exhibiting a high growth fraction. One-quarter of these patients had received adjuvant treatment. In the group exhibiting high levels of Ki-67 reactivity, significantly less favorable findings with respect to overall survival were observed among the untreated patients. The present results seem to confirm previous indications that antibody Ki-67 is of value in assessing the prognosis of N0 breast cancer.
我们使用单克隆抗体Ki-67测定了549例原发性乳腺癌的生长分数。就疾病进程而言，整个群体以及淋巴结阳性肿瘤之间出现了显著差异。我们特别关注了该组中的淋巴结阴性（N0）癌，目的是在这个总体预后良好的群体中区分出预后不良的亚组。由于临床事件相对较少，我们对这类肿瘤的研究结果未达到统计学意义；然而，对于生长分数高的肿瘤，出现了一种强烈的临床趋势，表明其总生存期和无病生存期预后不良。这些患者中有四分之一接受了辅助治疗。在Ki-67反应性高的组中，未接受治疗的患者在总生存期方面的结果明显较差。目前的结果似乎证实了先前的迹象，即抗体Ki-67在评估N0乳腺癌的预后方面具有价值。
